IMR Press / FBL / Volume 23 / Issue 2 / DOI: 10.2741/4594

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Strategies for reducing inflammation and promoting bone repair in arthritis

Show Less
1 Department of Basic Medical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN 47907, Indiana
2 Department of Biomedical Engineering, Indiana University Purdue University Indianapolis, Indianapolis, IN 46202, Indiana
Front. Biosci. (Landmark Ed) 2018, 23(2), 318–347;
Published: 1 January 2018
(This article belongs to the Special Issue Molecular approaches for cancer therapy)

Chronic forms of arthritis encompass many joint inflammatory disorders, including rheumatoid arthritis (RA), an autoimmune inflammatory disease, and osteoarthritis (OA), typically a ‘wear and tear’ condition that is now known to also have an inflammatory etiology. The impact of inflammation in the disease prognosis and joint degradation due to impaired repair mechanisms has long been recognized for RA, and now also for OA. Both forms of arthritis are prevalent chronic health conditions, and despite recent advances, their treatment still represents an unmet medical need because of safety and efficacy concerns with currently prescribed drugs. There is an urgent need to develop and test new drugs that selectively target inflamed joints and to control articular inflammation while preventing healthy tissue damage. The therapeutics developed for RA might be useful for OA, since studies in humans and animal models demonstrate a key role for chronic, low-grade inflammation in the pathogenesis of OA. In this review, we discuss current and emerging new therapies for management of inflammation and promotion of cartilage and/or bone repair in RA and OA.

Gene delivery
Back to top